
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2494500/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	POEMS Syndrome: Real World Experience in Diagnosis and Systemic Therapy - 108 Patients Multicenter Analysis. Clinical Lymphoma, Myeloma and Leukemia, 2022, 22, 297-304.	0.2	11
2	Ablation of VLA4 in multiple myeloma cells redirects tumor spread and prolongs survival. Scientific Reports, 2022, 12, 30.	1.6	12
3	Preferences and Priorities for Relapsed Multiple Myeloma Treatments Among Patients and Caregivers in the United States. Patient Preference and Adherence, 2022, Volume 16, 573-585.	0.8	4
4	Racial disparities in time to hematopoietic cell transplant among patients with hematologic malignancies at a large urban academic center. Bone Marrow Transplantation, 2022, 57, 1213-1215.	1.3	1
5	Screening recommendation adherence among first-degree relatives of individuals with colorectal cancer. Translational Behavioral Medicine, 2022, 12, 853-859.	1.2	1
6	Overall survival of patients with tripleâ€class refractory multiple myeloma treated with selinexor plus dexamethasone vs standard of care in <scp>MAMMOTH</scp> . American Journal of Hematology, 2021, 96, E5-E8.	2.0	20
7	Burden of Treatment Among Older Adults With Newly Diagnosed Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, e152-e159.	0.2	14
8	Renal failure among multiple myeloma patients utilizing carfilzomib and associated factors in the "real world― Annals of Hematology, 2021, 100, 1261-1266.	0.8	7
9	Autologous stem cell transplant for patients with multiple myeloma between ages 75 and 78. Bone Marrow Transplantation, 2021, 56, 2016-2018.	1.3	2
10	Co-evolution of tumor and immune cells during progression of multiple myeloma. Nature Communications, 2021, 12, 2559.	5.8	68
11	A deficit-accumulation frailty index predicts survival outcomes in patients with gynecologic malignancy. Gynecologic Oncology, 2021, 161, 700-704.	0.6	4
12	A single center retrospective study of daratumumab, pomalidomide, and dexamethasone as 2nd-line therapy in multiple myeloma. Leukemia and Lymphoma, 2021, 62, 3043-3046.	0.6	1
13	Bortezomib in first-line therapy is associated with falls in older adults with multiple myeloma. Journal of Geriatric Oncology, 2021, 12, 1005-1009.	0.5	4
14	A pilot study of 3D tissue-engineered bone marrow culture as a tool to predict patient response to therapy in multiple myeloma. Scientific Reports, 2021, 11, 19343.	1.6	6
15	Utilization of radiation therapy in multiple myeloma: trends and changes in practice. Annals of Hematology, 2021, 100, 735-741.	0.8	4
16	VLA4-Targeted Nanoparticles Hijack Cell Adhesion–Mediated Drug Resistance to Target Refractory Myeloma Cells and Prolong Survival. Clinical Cancer Research, 2021, 27, 1974-1986.	3.2	17
17	Disparities in health care affordability among childhood cancer survivors persist following the Affordable Care Act. Pediatric Blood and Cancer, 2021, 68, e29370.	0.8	0
18	3D Tissue-Engineered Bone Marrow Culture Predicts Patient Response to Drugs in Multiple Myeloma. Blood, 2021, 138, 2690-2690.	0.6	0

#	Article	IF	CITATIONS
19	Financial Toxicity Among Patients with Multiple Myeloma. Blood, 2021, 138, 4027-4027.	0.6	2
20	Single-Cell RNA-Seq Analysis of CD138-Depleted Bone Marrow Samples Reveals Genetic Alterations and Disease Progression Correlate with Tumor and Bone Marrow Immune Microenvironment in the Mmrf Commpass Study. Blood, 2021, 138, 2691-2691.	0.6	0
21	Cost differential associated with hospice use among older patients with multiple myeloma. Journal of Geriatric Oncology, 2020, 11, 88-92.	0.5	7
22	A comparison of three different approaches to defining frailty in older patients with multiple myeloma. Journal of Geriatric Oncology, 2020, 11, 311-315.	0.5	19
23	Maintenance therapy following salvage autologous stem cell transplant in patients with multiple myeloma. Bone Marrow Transplantation, 2020, 55, 1188-1190.	1.3	1
24	Adherence to Lenalidomide in Older Adults With Newly Diagnosed Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 98-104.e1.	0.2	16
25	Measuring cardiopulmonary complications of carfilzomib treatment and associated risk factors using the SEERâ€Medicare database. Cancer, 2020, 126, 808-813.	2.0	23
26	Primary refractory multiple myeloma: a real-world experience with 85 cases. Leukemia and Lymphoma, 2020, 61, 2868-2875.	0.6	6
27	Statins Reduce Mortality in Multiple Myeloma: A Population-Based US Study. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, e937-e943.	0.2	6
28	Geriatric assessment and quality of life changes in older adults with newly diagnosed multiple myeloma undergoing treatment. Journal of Geriatric Oncology, 2020, 11, 1279-1284.	0.5	10
29	Evolution and structure of clinically relevant gene fusions in multiple myeloma. Nature Communications, 2020, 11, 2666.	5.8	31
30	Variability in Cytogenetic Testing for Multiple Myeloma: A Comprehensive Analysis From Across the United States. JCO Oncology Practice, 2020, 16, e1169-e1180.	1.4	8
31	Racial Disparities in the Utilization of Novel Agents for Frontline Treatment of Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 647-651.	0.2	15
32	The characteristics, treatment patterns, and outcomes of older adults aged 80 and over with multiple myeloma. Journal of Geriatric Oncology, 2020, 11, 1274-1278.	0.5	12
33	DCEP and bendamustine/prednisone as salvage therapy for quad- and penta-refractory multiple myeloma. Annals of Hematology, 2020, 99, 1041-1048.	0.8	12
34	A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry. Blood Advances, 2020, 4, 181-190.	2.5	16
35	Mobilization Strategies: HPC(A) Collections for Allogeneic Hematopoietic Cell Transplants. Advances and Controversies in Hematopoietic Transplantation and Cell Therapy, 2020, , 63-80.	0.0	0
36	Myeloma Cell Associated Therapeutic Protein Discovery Using Single Cell RNA-Seq Data. Blood, 2020, 136, 4-5.	0.6	0

#	Article	IF	CITATIONS
37	Decision Making Factors That Influence Treatment Options for an Autologous Stem Cell Transplant for Older Adults (aged 65-75) with Newly Diagnosed Multiple Myeloma: A Mixed Methods Study. Blood, 2020, 136, 13-13.	0.6	1
38	D-Dimer Improves Risk Prediction of Venous Thromboembolism in Patients with Multiple Myeloma. Blood, 2020, 136, 26-27.	0.6	2
39	A Preliminary Assessment of HeterozygousCFHR3-CFHR1Deletion As a Permissive Mutation in Carfilzomib-Induced Atypical Hemolytic Uremic Syndrome. Blood, 2020, 136, 8-9.	0.6	0
40	Multiple myeloma in patients up to 30Âyears of age: a multicenter retrospective study of 52 cases. Leukemia and Lymphoma, 2019, 60, 471-476.	0.6	13
41	Secondary plasma cell leukemia: a multicenter retrospective study of 101 patients. Leukemia and Lymphoma, 2019, 60, 118-123.	0.6	23
42	A Mixed-Methods Study of Stem Cell Transplantation Utilization for Newly Diagnosed Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e521-e525.	0.2	4
43	EZH2 Overexpression in Multiple Myeloma: Prognostic Value, Correlation With Clinical Characteristics, and Possible Mechanisms. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, 744-750.	0.2	7
44	Next Generation Sequencing-based Validation of the Revised International Staging System for Multiple Myeloma: An Analysis of the MMRF CoMMpass Study. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, 285-289.	0.2	17
45	A Phase I Study of the Safety and Feasibility of Bortezomib in Combination With G-CSF for Stem Cell Mobilization in Patients With Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e588-e593.	0.2	6
46	Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia, 2019, 33, 2266-2275.	3.3	385
47	A Phase I/II Trial of Carfilzomib, Pegylated Liposomal Doxorubicin, and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma. Clinical Cancer Research, 2019, 25, 3776-3783.	3.2	14
48	African American patients may or may not have poorer response rates after monoclonal antibody treatment: Overreliance on P values in underpowered studies. Cancer, 2019, 125, 2321-2322.	2.0	0
49	Overall Survival of Triple Class Refractory, Penta-Exposed Multiple Myeloma (MM) Patients Treated with Selinexor Plus Dexamethasone or Conventional Care: A Combined Analysis of the STORM and Mammoth Studies. Blood, 2019, 134, 3125-3125.	0.6	10
50	Ixazomib or Lenalidomide Maintenance Following Autologous Stem Cell Transplantation and Ixazomib, Lenalidomide, and Dexamethasone (IRD) Consolidation in Patients with Newly Diagnosed Multiple Myeloma: Results from a Large Multi-Center Randomized Phase II Trial. Blood, 2019, 134, 602-602.	0.6	10
51	Single-Cell Transcriptomic and Proteomic Diversity in Multiple Myeloma. Blood, 2019, 134, 5531-5531.	0.6	1
52	Analysis of Falls in Older Adults with Multiple Myeloma Undergoing First-Line Therapy. Blood, 2019, 134, 5886-5886.	0.6	1
53	Geriatric Assessment and Frailty Changes in Older Patients with Newly-Diagnosed Multiple Myeloma Undergoing Treatment. Blood, 2019, 134, 4774-4774.	0.6	1
54	Single-Cell Pathway Enrichment and Regulatory Profiling of Multiple Myeloma across Disease Stages. Blood, 2019, 134, 364-364.	0.6	0

#	Article	IF	CITATIONS
55	Comprehensive Investigation of White Blood Cell and Gene Expression Profiles As Risk Factors for Multiple Myeloma in African Americans. Blood, 2019, 134, 4379-4379.	0.6	0
56	Utilization of Autologous Stem Cell Transplantation in Older Patients with Newly Diagnosed Multiple Myeloma. Blood, 2019, 134, 5701-5701.	0.6	0
57	The Ire of IRE1α: Overexpression of IRE1α at Myeloma Diagnosis Is Associated with Decreased Survival While Downregulation of IRE1α Expression Is Predictive of Therapy Resistance. Blood, 2019, 134, 4351-4351.	0.6	1
58	Undertreatment of Older Patients With Newly Diagnosed Multiple Myeloma in the Era of Novel Therapies. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, 219-224.	0.2	34
59	Cellular stressors contribute to the expansion of hematopoietic clones of varying leukemic potential. Nature Communications, 2018, 9, 455.	5.8	150
60	Prognostic indicators in primary plasma cell leukaemia: a multicentre retrospective study of 117 patients. British Journal of Haematology, 2018, 180, 831-839.	1.2	41
61	Falls in older adults with multiple myeloma. European Journal of Haematology, 2018, 100, 273-278.	1.1	15
62	Development of a Medicare Health Outcomes Survey Deficit-Accumulation Frailty Index and Its Application to Older Patients With Newly Diagnosed Multiple Myeloma. JCO Clinical Cancer Informatics, 2018, 2, 1-13.	1.0	27
63	The efficacy of salvage autologous stem cell transplant among patients with multiple myeloma who received maintenance therapy post initial transplant. Bone Marrow Transplantation, 2018, 53, 1483-1486.	1.3	12
64	Multiple Myeloma Patients Ineligible for Randomized Controlled Trials Have Poorer Outcomes Irrespective of Treatment. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, e363-e364.	0.2	4
65	A multiple myeloma-specific capture sequencing platform discovers novel translocations and frequent, risk-associated point mutations in IGLL5. Blood Cancer Journal, 2018, 8, 35.	2.8	41
66	lxazomib-Lenalidomide-Dexamethasone (IRd) Consolidation Following Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma: A Large Multi-Center Phase II Trial. Blood, 2018, 132, 123-123.	0.6	6
67	Natural History of Patients with Multiple Myeloma Refractory to CD38-Targeted Monoclonal Antibody-Based Treatment. Blood, 2018, 132, 3233-3233.	0.6	6
68	Natural History of Patients with Multiple Myeloma Refractory to Elotuzumab and Outcomes of Subsequent Therapy with Anti-CD38 Monoclonal Antibodies. Blood, 2018, 132, 3303-3303.	0.6	1
69	Patient Treatment Preferences for Relapsed/Refractory Multiple Myeloma: Are Patients Willing to Trade Off Efficacy for Tolerability?. Blood, 2018, 132, 614-614.	0.6	5
70	Subsequent Treatment Outcomes of Multiple Myeloma Refractory to CD38-Monoclonal Antibody Therapy. Blood, 2018, 132, 2015-2015.	0.6	10
71	Increasing Daratumumab Frequency As a Way to Restore Responses- a Retrospective Case Study. Blood, 2018, 132, 5666-5666.	0.6	1
72	D.C.E.P. in Patients with Quad- or Penta-Refractory Multiple Myeloma. Blood, 2018, 132, 2021-2021.	0.6	1

#	Article	IF	CITATIONS
73	The Characteristics, Treatment Patterns, and Outcomes of Older Adults with Multiple Myeloma. Blood, 2018, 132, 4463-4463.	0.6	0
74	Disparities in Healthcare Resource Utilization for Multiple Myeloma. Blood, 2018, 132, 4793-4793.	0.6	1
75	Characterization of Germline Variants in Multiple Myeloma. Blood, 2018, 132, 4499-4499.	0.6	0
76	A Study of Tbo-Filgrastim (Granix) to Disrupt the Bone Marrow Microenvironment in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation. Blood, 2018, 132, 2146-2146.	0.6	0
77	Bendamustine in Patients with Quad- and Penta-Refractory Multiple Myeloma. Blood, 2018, 132, 5627-5627.	0.6	1
78	The Effect of Maintenance Therapy Following Salvage Autologous Stem Cell Transplant in Multiple Myeloma Patients. Blood, 2018, 132, 3439-3439.	0.6	0
79	Overcoming Drug Resistance in Myeloma By Synchronized Delivery of Therapeutic and Bone Marrow Disrupting Agents By Nanoparticles Targeting Tumor-Associated Endothelium. Blood, 2018, 132, 1931-1931.	0.6	Ο
80	Comprehensive Multi-Omics Analysis of Gene Fusions in a Large Multiple Myeloma Cohort. Blood, 2018, 132, 1898-1898.	0.6	0
81	Clinical Validation of Treatment Response Predictions Using a Genomics Driven Computational Biology Modelling Multiple Myeloma Algorithm. Blood, 2018, 132, 1893-1893.	0.6	Ο
82	The impact of diabetes mellitus and other comorbidities on hematopoietic stem cell collection and hematologic recovery post-transplantation. Leukemia and Lymphoma, 2017, 58, 241-243.	0.6	0
83	Racial disparities in treatment use for multiple myeloma. Cancer, 2017, 123, 1590-1596.	2.0	77
84	lgM myeloma: A multicenter retrospective study of 134 patients. American Journal of Hematology, 2017, 92, 746-751.	2.0	45
85	Mobilization of allogeneic peripheral blood stem cell donors with intravenous plerixafor mobilizes a unique graft. Blood, 2017, 129, 2680-2692.	0.6	66
86	Fresh or Cryopreserved CD34 + -Selected Mobilized Peripheral Blood Stem and Progenitor Cells for the Treatment of Poor Graft Function after Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2017, 23, 1072-1077.	2.0	39
87	Similar survival outcomes in patients with biclonal versus monoclonal myeloma: a multi-institutional matched case-control study. Annals of Hematology, 2017, 96, 1693-1698.	0.8	7
88	Results of a Prospective Randomized, Open-Label, Noninferiority Study of Tbo-Filgrastim (Granix) versus Filgrastim (Neupogen) in Combination with Plerixafor for Autologous Stem Cell Mobilization in Patients with Multiple Myeloma and Non-Hodgkin Lymphoma. Biology of Blood and Marrow Transplantation, 2017, 23, 2065-2069.	2.0	19
89	Donor-Derived Smoldering Multiple Myeloma following a Hematopoietic Cell Transplantation for AML. Case Reports in Hematology, 2017, 2017, 1-3.	0.3	3
90	Development of an Algorithm to Distinguish Smoldering Versus Symptomatic Multiple Myeloma in Claims-Based Data Sets. JCO Clinical Cancer Informatics, 2017, 1, 1-8.	1.0	12

#	Article	IF	CITATIONS
91	Race Is Associated with Bortezomib but Not Lenalidomide Utilization during First-Line Treatment of Multiple Myeloma. Blood, 2017, 130, 862-862.	0.6	0
92	Factors Determining Utilization of Stem Cell Transplant (SCT) for Initial Therapy of Multiple Myeloma (MM) By Patient Race: Exploring Intra-Racial Healthcare Disparities. Blood, 2017, 130, 860-860.	0.6	0
93	Remobilization of hematopoietic stem cells in healthy donors for allogeneic transplantation. Transfusion, 2016, 56, 2331-2335.	0.8	7
94	Central nervous system involvement by multiple myeloma: A multiâ€institutional retrospective study of 172 patients in daily clinical practice. American Journal of Hematology, 2016, 91, 575-580.	2.0	83
95	Phase I study of azacitidine following donor lymphocyte infusion for relapsed acute myeloid leukemia post allogeneic stem cell transplantation. Leukemia Research, 2016, 49, 1-6.	0.4	31
96	A phase I study of carfilzomib for relapsed or refractory acute myeloid and acute lymphoblastic leukemia. Leukemia and Lymphoma, 2016, 57, 728-730.	0.6	14
97	A phase I study of thymoglobulin for relapsed or refractory multiple myeloma. Leukemia and Lymphoma, 2016, 57, 453-455.	0.6	0
98	The Efficacy of Salvage Autologous Stem Cell Transplant for Patients with Multiple Myeloma Who Received Maintenance Therapy Following Initial Transplant. Blood, 2016, 128, 3563-3563.	0.6	2
99	IgM Myeloma: A Multicenter Retrospective Study of 159 Patients. Blood, 2016, 128, 3276-3276.	0.6	0
100	Next Generation Sequencing Based Revised International Staging System (R-ISS) for Multiple Myeloma. Blood, 2016, 128, 2349-2349.	0.6	0
101	Uncovering Clonal and Subclonal Druggable Targets in Multiple Myeloma Using Omic Data. Blood, 2016, 128, 2084-2084.	0.6	0
102	Bendamustine, lenalidomide, and dexamethasone (BRD) is highly effective with durable responses in relapsed multiple myeloma. American Journal of Hematology, 2015, 90, 1106-1110.	2.0	19
103	Personalization of cancer treatment using predictive simulation. Journal of Translational Medicine, 2015, 13, 43.	1.8	23
104	Socioeconomic status is independently associated with overall survival in patients with multiple myeloma. Leukemia and Lymphoma, 2015, 56, 2643-2649.	0.6	47
105	Diabetes Limits Stem Cell Mobilization Following G-CSF but Not Plerixafor. Diabetes, 2015, 64, 2969-2977.	0.3	50
106	Maintenance Therapy with Decitabine after Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndrome. Biology of Blood and Marrow Transplantation, 2015, 21, 1761-1769.	2.0	143
107	Re: Disparities in Utilization of Autologous Hematopoietic Cell Transplantation for Treatment of Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2015, 21, 1153-1154.	2.0	14
108	CD34+-Selected Infusions of Fresh or Cryopreserved Peripheral Blood Stem Cells for the Treatment of Poor Graft Function Following Allogeneic Hematopoietic Stem Cell Transplant. Blood, 2015, 126, 3098-3098.	0.6	1

#	Article	IF	CITATIONS
109	A Randomized Trial of Tbo-Filgrastim Versus Filgrastim for Autologous Stem Cell Mobilization in Patients with Multiple Myeloma or Non-Hodgkin Lymphoma. Blood, 2015, 126, 516-516.	0.6	3
110	A Second Generation, Multiple Myeloma-Specific, Targeted Sequencing Platform for Detecting Translocations, Copy Number Alterations, and Single Nucleotide Variants. Blood, 2015, 126, 4207-4207.	0.6	0
111	A phase II study of V-BEAM as conditioning regimen before second auto-SCT for multiple myeloma. Bone Marrow Transplantation, 2014, 49, 1366-1370.	1.3	6
112	Phase I study of cladribine, cytarabine, granulocyte colony stimulating factor (CLAG regimen) and midostaurin and all-trans retinoic acid in relapsed/refractory AML. International Journal of Hematology, 2014, 99, 272-278.	0.7	32
113	PI3KCA plays a major role in multiple myeloma and its inhibition with BYL719 decreases proliferation, synergizes with other therapies and overcomes stroma-induced resistance. British Journal of Haematology, 2014, 165, 89-101.	1.2	34
114	The characteristics and outcomes of patients with multiple myeloma dual refractory or intolerant to bortezomib and lenalidomide in the era of carfilzomib and pomalidomide. Leukemia and Lymphoma, 2014, 55, 337-341.	0.6	12
115	Deep Sequencing Reveals Myeloma Cells in Peripheral Blood in Majority of Multiple Myeloma Patients. Clinical Lymphoma, Myeloma and Leukemia, 2014, 14, 131-139.e1.	0.2	54
116	Therapy Personalization Using Predictive Simulation Approach with Ex-Vivo Clinical Validations. Blood, 2014, 124, 2232-2232.	0.6	1
117	Treatment Advances for Multiple Myeloma Have Disproportionally Benefited Patients Who Are Young, White, and Have Higher Socioeconomic Status. Blood, 2014, 124, 555-555.	0.6	24
118	A Study of High Dose Lenalidomide Induction and Low Dose Lenalidomide Maintenance for Patients with Hypomethylating Agent Refractory MDS. Blood, 2014, 124, 1931-1931.	0.6	4
119	Donor-to-Recipient Weight Ratio Is Independently Associated with CD34+ Yield in Healthy Donors Undergoing Peripheral Blood Stem Cell Collection for Allogeneic Transplantation. Blood, 2014, 124, 2456-2456.	0.6	1
120	Front-Line Radiotherapy Is Associated with Shortened Survival in Newly Diagnosed Multiple Myeloma Patients. Blood, 2014, 124, 5696-5696.	0.6	0
121	A Phase I Study of Carfilzomib for Relapsed or Refractory Acute Myeloid and Acute Lymphoblastic Leukemia. Blood, 2014, 124, 5292-5292.	0.6	Ο
122	A Phase I Study of Carfilzomib and Pegylated Liposomal Doxorubicin for Relapsed or Refractory Multiple Myeloma. Blood, 2014, 124, 4731-4731.	0.6	0
123	Remobilization with G-CSF Is Less Effective Than the Initial Mobilization in Healthy Donors Undergoing Peripheral Blood Stem Cell Collection for Allogeneic Transplantation. Blood, 2014, 124, 850-850.	0.6	Ο
124	A Phase II Study Of V-BEAM (Bortezomib, Carmustine, Etoposide, Cytarabine, and Melphalan) As Conditioning Regimen Prior To Second Autologous Stem Cell Transplantation For Multiple Myeloma. Blood, 2013, 122, 5492-5492.	0.6	3
125	Genomic Landscape of Immunoglobulin Light Chain (AL) Amyloidosis and Comparative Analyses with Related Malignant Plasma Cell Disorder- Multiple Myeloma. Blood, 2011, 118, 809-809.	0.6	0
126	The Multiple Myeloma Research Consortium (MMRC): Accelerated Start up and Accrual Metrics Speeds Drug Development. Blood, 2011, 118, 1024-1024.	0.6	0

#	Article	IF	CITATIONS
127	High Throughput Digital Quantification of Genomic Copy Number Alterations in Multiple Myeloma. Blood, 2011, 118, 1830-1830.	0.6	0
128	The Multiple Myeloma Research Consortium (MMRC) Model: Reduced Time to Trial Activation and Improved Accrual Metrics Blood, 2010, 116, 3803-3803.	0.6	2
129	A Single-Institution Randomized Prospective Trial of Pre-Emptive Therapy with Oral Valganciclovir Compared with IV Ganciclovir for Cytomegalovirus Infection after Allogeneic Hematopoietic Stem Cell Transplant (aHSCT), Delayed until Viral Load (VL) >10,000 Copies/Ml or >5,000 Copies/Ml X 2, Blood, 2008, 112, 4340-4340,	0.6	0